George P Kim

George P Kim, MD

Clinical Professor

Department: MD-HEMATOLOGY/ONCOLOGY
Business Phone: (352) 273-7832
Business Email: george.kim@ufl.edu

About George P Kim

Dr. George Kim is a board certified medical oncologist specializing in gastrointestinal oncology. He recently joined the University of Florida Health Cancer Center in Gainesville, Florida. After receiving a medical degree from the University of Vermont, College of Medicine, he completed internship and residency at the Johns Hopkins Hospital. Dr. Kim then completed medical oncology fellowship at the National Cancer Institute where he conducted laboratory research involving microsatellite instability and analyzed archived specimens from several National Surgical Breast and Bowel Project colorectal cancer phase III trials. This published work helps define the predictive and prognostic roles of high-degree microsatellite instability in the adjuvant setting. He subsequently joined Mayo Clinic Florida and served as the Director of the Gastrointestinal Cancer Section, the Phase I Program and the Research Affiliates Network. He also served as the Director of GI Oncology at the George Washington University Cancer Center. Dr. Kim served as the principal investigator of several GI cancer trials conducted through the North Central Cancer Treatment Group, Phase 2 Consortium and Mayo Clinic Cancer Center involving colorectal, pancreatic and hepatocellular cancers. These trials focused on combining contemporary chemotherapy with novel biologic agents and had significant focus on predictive markers. Dr. Kim was also a principal investigator in Mayo Clinic Pancreas Cancer SPORE and funded to study predictive markers of gemcitabine activity. He served on U.S. Intergroup committees, both Pancreas and Colon Cancer Task Forces. He published numerous reports on the treatment of these cancers and on the discovery of predictive markers. Dr. Kim authored numerous peer-reviewed manuscripts and multiple book chapters. He served on patient advocacy boards for stomach and pancreatic cancer.

Research Profile

Open Researcher and Contributor ID (ORCID)

0009-0002-7512-270X

Publications

2020
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.
Pancreatology : official journal of the International Association of Pancreatology (IAP) … [et al.]. 20(1):101-109 [DOI] 10.1016/j.pan.2019.11.011. [PMID] 31787526.
2019
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
The oncologist. 24(5):589-e160 [DOI] 10.1634/theoncologist.2018-0878. [PMID] 30679315.
2017
Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Expert review of clinical pharmacology. 10(5):559-565 [DOI] 10.1080/17512433.2017.1302330. [PMID] 28286977.
2015
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.
Investigational new drugs. 33(4):963-8 [DOI] 10.1007/s10637-015-0246-2. [PMID] 25952464.
2015
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
Journal of oncology practice. 11(4):332-7 [DOI] 10.1200/JOP.2014.001750. [PMID] 25991639.
2014
Changes in the care of non-small-cell lung cancer after audit and feedback: the Florida initiative for quality cancer care.
Journal of oncology practice. 10(4):e247-54 [DOI] 10.1200/JOP.2013.001275. [PMID] 24737876.
2014
Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.
Investigational new drugs. 32(4):710-6 [DOI] 10.1007/s10637-014-0096-3. [PMID] 24740268.
2014
Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab.
Pancreas. 43(3):343-9 [DOI] 10.1097/MPA.0000000000000095. [PMID] 24622062.
2013
Complications after 90Y microsphere radioembolization for unresectable hepatic tumors: An evaluation of 112 patients.
Brachytherapy. 12(6):573-9 [DOI] 10.1016/j.brachy.2013.05.008. [PMID] 23953810.
2012
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.
Investigational new drugs. 30(1):387-94 [DOI] 10.1007/s10637-010-9532-1. [PMID] 20839030.
2012
Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(4):406-12 [DOI] 10.1200/JCO.2011.39.2563. [PMID] 22203756.
2012
Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial.
American journal of clinical oncology. 35(5):418-23 [PMID] 21555932.
2012
Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 18(5):594-601 [DOI] 10.1002/lt.22462. [PMID] 22140024.
2011
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Journal of the National Cancer Institute. 103(11):863-75 [DOI] 10.1093/jnci/djr153. [PMID] 21597022.
2011
Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in Florida.
Journal of oncology practice. 7(6):e25-31 [PMID] 22379428.
2011
Retransplantation for donor-derived neuroendocrine tumor.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 17(1):83-7 [DOI] 10.1002/lt.22196. [PMID] 21254348.
2009
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(17):2848-54 [DOI] 10.1200/JCO.2008.20.4552. [PMID] 19380443.
2008
Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(21):3511-6 [DOI] 10.1200/JCO.2007.15.8782. [PMID] 18640932.
2007
Oxaliplatin in the treatment of colorectal cancer.
Expert opinion on drug metabolism & toxicology. 3(2):281-94 [PMID] 17428157.
2007
Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(7):767-72 [PMID] 17228023.
2007
Treatment options for hepatobiliary and pancreatic cancer.
Mayo Clinic proceedings. 82(5):628-37 [PMID] 17493429.
2005
Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.
Clinical colorectal cancer. 5 Suppl 2:S89-97 [PMID] 16336754.

Grants

Jun 2023 ACTIVE
UF Health Cancer Center Support Grant
Role: Other
Funding: NATL INST OF HLTH NCI

Contact Details

Phones:
Business:
(352) 273-7832
Emails:
Business:
george.kim@ufl.edu
Addresses:
Business Street:
PO Box 100278
GAINESVILLE FL 32610